Slayback Pharma
About:
Slayback Pharma believe every pharmaceutical product exhibits its own unique personality.
Website: http://www.slayback-pharma.com/
Top Investors: Kohlberg Kravis Roberts, Everstone
Description:
Slayback is founded on the principle of “connecting the dots”. This principle translates into their philosophy of connecting one idea with another. The idea is to conceptualize and develop complex generic and specialty drugs. They focus on products that are challenging and highly complex to develop and/or manufacture. It could be a complex oil-in-water emulsion or a sterile long acting injectable using nano-spheres or sterile suspensions with complex particle physics. They have also worked on complex hormonal products with challenging cross-contamination issues. They aim to optimize the use of technology and potential (generated from a strong experience in this field) to develop a value proposition for their customers. Through this process of drug development, they remotely aim at reducing the cost of therapy by bringing expensive branded drugs within the reach of patients.
$110M
$1M to $10M
Princeton, New Jersey, United States
2011-01-01
contact(AT)slayback-pharma.com
Ajay K Singh
101-250
2020-01-06
Private
© 2025 bioDAO.ai